



# Covid-19 impact On pancreatic Cancer Care pathway

*A National, Pan-Speciality, Multi-Centre Study of the Impact of SARS-CoV-2 on New Diagnosed Pancreatic Cancer Pathways and Treatment*



## Background:

- Pancreatic cancer is aggressive with most patients presenting with unresectable disease.
- There are concerns that patients with pancreatic cancer did not receive optimal treatment due to service constraints during the SARS-CoV-2 pandemic, but the current impact is unknown.

**Aim:** To assess the impact of SARS-CoV-2 pandemic on newly diagnosed pancreatic cancer patients in the UK

**Methods:** (1) Patients identified at MDT (2) Only patients presenting primarily to the centre (3) 6 and 12 month follow-up

## DATA COLLECTION:

Pre-pandemic: **7<sup>th</sup> January to 3<sup>rd</sup> March 2019**

Peak-pandemic: **16<sup>th</sup> March to 10<sup>th</sup> May 2020**

6 and 12-month follow-up

## PATIENT INCLUSION:



Newly diagnosed pancreatic cancer

Only patients **presenting** to the centre are included, **not those referred** from other centres

## PRIMARY OUTCOME:



**Rate of receipt of chemotherapy** at 6 and 12 month during peak of **SARS-CoV-2** compared with **pre-pandemic** rates.